TD Cowen Reiterates Buy Rating on CVS Health (CVS); 'MA Final Rate Notice Positive'

TD Cowen analyst Charles Rhyee reiterated a Buy rating and $80.00 price target on CVS Health (NYSE: CVS).

The analyst commented: "MA Final Rate Notice Positive for CVS's MA Recovery and '26 Outlook; We reiterate our Buy rating on CVS as CMS's Final rate notice of +5.06% represents a ~280bps increase from the advance notice (+2.23%). We expect this higher than expected increase will help accelerate CVS's MA margin recovery. We believe the increase represents up to $1 of upside to our '26 adj. EPS est. of $6.93, although we expect CVS likely uses a portion of the increase to improve benefits."

For an analyst ratings summary and ratings history on CVS Health click here. For more ratings news on CVS Health click here.

Shares of CVS Health closed at $63.85 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• UBS Reiterates Buy Rating on HF Sinclair (DINO)
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)